Sell4

Adaptive Biotechnologies Corp

ADPT

Total Value

$22.7M

Net $14.9M sold

Filing Date

Aug 19, 2026

4 transactions

Sales

$14.9M

4 transactions

Trade Summary

On Aug 17, 2026 through Aug 18, 2026, ROBINS CHAD M, CEO and Chairman, Director, sold $22.7M of Adaptive Biotechnologies Corp (ADPT) across 4 transactions. The filing covers Common Stock and reflects net selling of $14.9M. Reported prices ranged from $6.55 to $25.57. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

ADPT daily price with the insider's sale marked at $24.80.

Sold near the 6-month high · the stock trades 2% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: ROBINS CHAD M
Role: CEO and Chairman, Director
Location: SEATTLE, WA

Filing Details

Filing Date: Aug 19, 2026
Transaction Date: Aug 17, 2026
Accession Number: 0001780649-26-000014
Form Type: 4
Net Trading Amount: -$14.9M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 17, 2026	Common Stock	321,324	$6.55	Exercise	$2.1M
Aug 17, 2026	Common Stock	318,799	$25.08	Sale	$8.0M
Aug 17, 2026	Common Stock	2,525	$25.57	Sale	$64.6K
Aug 18, 2026	Common Stock	278,676	$6.55	Exercise	$1.8M
Aug 18, 2026	Common Stock	278,472	$24.48	Sale	$6.8M
Aug 18, 2026	Common Stock	204	$25.14	Sale	$5.1K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 17, 2026	ADPT derivative	321,324	$6.55	Exercise	$2.1M
Aug 18, 2026	ADPT derivative	278,676	$6.55	Exercise	$1.8M

Want live alerts when ROBINS CHAD M trades again?

Download Insider Trades to track ADPT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(F2)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(F3)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(F4)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(F5)The option was fully vested and exercisable and would have expired on February 7, 2028.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS CHAD M

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

98109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		M		321,324	A	$6.55	2,501,842	D
Common Stock	08/17/2026		S		318,799	D	$25.08⁽¹⁾	2,183,043	D
Common Stock	08/17/2026		S		2,525	D	$25.57⁽²⁾	2,180,518	D
Common Stock	08/18/2026		M		278,676	A	$6.55	2,459,194	D
Common Stock	08/18/2026		S		278,472	D	$24.48⁽³⁾	2,180,722	D
Common Stock	08/18/2026		S		204	D	$25.14⁽⁴⁾	2,180,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.55	08/17/2026		M			321,324	⁽⁵⁾	02/07/2028	Common Stock	321,324	$0	278,676	D
Stock Option (right to buy)	$6.55	08/18/2026		M			278,676	⁽⁵⁾	02/07/2028	Common Stock	278,676	$0	0	D

Explanation of Responses:

1. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The option was fully vested and exercisable and would have expired on February 7, 2028.

	/s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001780649-26-000014.

Adaptive Biotechnologies Corp

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when ROBINS CHAD M trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade